KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Other Accumulated Expenses (2018 - 2025)

Historic Other Accumulated Expenses for Aurinia Pharmaceuticals (AUPH) over the last 9 years, with Q3 2025 value amounting to $2.5 million.

  • Aurinia Pharmaceuticals' Other Accumulated Expenses rose 5735.85% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 5735.85%. This contributed to the annual value of $1.5 million for FY2024, which is 3588.78% down from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' Other Accumulated Expenses stood at $2.5 million, which was up 5735.85% from $2.5 million recorded in Q2 2025.
  • Over the past 5 years, Aurinia Pharmaceuticals' Other Accumulated Expenses peaked at $6.5 million during Q3 2021, and registered a low of $502000.0 during Q1 2022.
  • Moreover, its 5-year median value for Other Accumulated Expenses was $2.0 million (2022), whereas its average is $2.2 million.
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' Other Accumulated Expenses crashed by 8878.56% in 2022, and later skyrocketed by 29422.31% in 2023.
  • Quarter analysis of 5 years shows Aurinia Pharmaceuticals' Other Accumulated Expenses stood at $4.4 million in 2021, then plummeted by 54.31% to $2.0 million in 2022, then rose by 17.46% to $2.4 million in 2023, then plummeted by 35.89% to $1.5 million in 2024, then soared by 63.42% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $2.5 million for Q2 2025, and $1.7 million during Q1 2025.